Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.58 |
| ▸ | HTR2C | P28335 | 4/20 | 0.58 |
| ▸ | HTR1A | P08908 | 3/20 | 0.58 |
| ▸ | HTR2B | P41595 | 3/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | HTR1E | P28566 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20970923 | 1.00 | HTR2A (0.58) | HTR2AHTR2CHTR1AHTR2BMTNR1A | |
| SCHEMBL25541553 | 0.90 | HTR2A (0.70) | HTR2AHTR2CHTR1AHTR2BMTNR1A | |
| SCHEMBL31742680 | 0.90 | HTR2A (0.70) | HTR2AHTR2CHTR1AHTR2BMTNR1A | |
| SCHEMBL25459268 | 0.90 | HTR2A (0.55) | HTR2AHTR2CHTR1AHTR2BMTNR1A | |
| SCHEMBL25459274 | 0.89 | HTR2A (0.59) | HTR2AHTR2CHTR1AHTR2BMTNR1A | |
| SCHEMBL25459270 | 0.89 | HTR2A (0.54) | HTR2AHTR2CHTR1AHTR2BMTNR1A | |
| SCHEMBL25459146 | 0.88 | HTR2A (0.58) | HTR2AHTR2CHTR1AHTR2BMTNR1A | |
| SCHEMBL30681648 | 0.86 | HTR2A (0.51) | HTR2AHTR2CHTR1AHTR2BMTNR1A | |
| SCHEMBL31066854 | 0.82 | HTR2A (0.60) | HTR2AHTR2CHTR1AHTR2BMTNR1A | |
| SCHEMBL23057152 | 0.79 | MTNR1A (0.53) | HTR2AHTR2CHTR1AHTR2BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611417-B1 | Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines | Convergent Health Sciences LLC: (US) | 2026-04-28 | — | — | US | disclosed |
| US-12503713-B1 | Stabilization of tryptamines by denaturing enzymes, optimizing ionization states, and controlling confounding variables | Convergent Health Sciences LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-12497637-B1 | Stabilization of tryptamines by denaturing enzymes, optimizing ionization states, and controlling confounding variables | Convergent Health Sciences LLC (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| US-20240366638-A1 | PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS | SYNAPTIVE THERAPEUTICS, LLC | 2024-11-07 | — | — | US | disclosed |
| EP-4452986-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | Kuleon LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230405026-A1 | A Method of Treating Depression by Immune Modulation | MYND LIFE SCIENCES INC (CA) | 2023-12-21 | — | — | US | disclosed |
| WO-2023225043-A1 | TRICYCLIC AND TETRACYCLIC SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4251181-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | Wesana Health Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4251139-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | Wesana Health Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023122135-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023023298-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20220331344-A1 | ORAL FORMULATIONS OF PSYCHOTROPIC MACROFUNGUS BOTANICAL EXTRACTS WITH MOUTHFEEL EXPERIENCE ENHANCERS | CHICAGO ATLANTIC ADMIN, LLC | 2022-10-20 | — | — | US | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115796-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611417-B1 | Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines | PLCB1, PHKG1, PLCB3 | HTR2A 105/4885HTR2C 39/4885HTR1A 91/4885 |
| US-20220331344-A1 | ORAL FORMULATIONS OF PSYCHOTROPIC MACROFUNGUS BOTANICAL EXTRACTS WITH MOUTHFEEL EXPERIENCE ENHANCERS | MB, MLEC, NISCH | HTR2A 53/4885HTR2C 26/4885HTR1A 76/4885 |
| US-20240366638-A1 | PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS | HTR1B, HTR2B, PNMT | HTR2A 5/4885HTR2C 4/4885HTR1A 8/4885 |
| US-20230405026-A1 | A Method of Treating Depression by Immune Modulation | ABCF1, ABCF2, ABCB4 | HTR2A 377/4885HTR2C 1196/4885HTR1A 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.